Skip to content
Hugin
One small clear glass vial standing alone on a dark laboratory bench under a single overhead light.

Hugin News

FDA opened applications for a pilot meant to shorten the road to a first-in-human drug trial. Eight to ten pairs get in, the window closes October 30, and the agency keeps every power it had.

2 min read

Original editorial artwork generated for Hugin.

On September 15 the FDA announced the final design of its Expedited Investigational New Drug Pilot and began accepting applications. Drug sponsors apply paired with a qualified research institution; the FDA will review and accept individual components of an IND application on a rolling basis during the pre-IND phase rather than waiting for the whole package, with the aim of finding problems early enough to avoid a clinical hold during the 30-day IND period. The agency says first-in-human trials 'may take up to two years to complete in the United States' and are finished faster in China and Australia. Applications close October 30, 2026; the FDA expects 8-10 sponsor-institution pairs in the first cohort, and states it retains full regulatory authority throughout, including whether a trial may proceed.

fdaclinical-trialsdrug-developmentdeadlinehealth
1source receipts1source hosts2 minread timelinkedprimary source

An investigational new drug application is the document that stands between a laboratory result and the first person who takes the compound. This pilot is about how that document gets reviewed.

What is being tried

Not a lowered standard. A different order of operations.

Under the pilot, a drug sponsor applies paired with a qualified research institution, and those institutions "will bring specialized and substantial scientific expertise to the IND application preparation process allowing the FDA to review and accept individual components on a rolling review during the pre-IND phase, rather than waiting for all components to begin review."

The stated purpose of the rolling review is to find the problem before it becomes a stop: it tests "whether this allows issues with an IND application to be identified and resolved in real time sooner — thereby reducing the risk of the FDA placing the first-in-human clinical trial protocol on hold (i.e., may not proceed) during the 30-day IND, and making the path from scientific discovery to first-in-human trial faster, more predictable, and more collaborative."

The dates and the size
Applications open announced September 15, 2026
Applications close October 30, 2026
Expected first cohort "8–10 Sponsor-QRI pairs"

Sponsors submit; sponsors and institutions apply as a pair. "Applications will undergo review by FDA scientific experts."

The claim underneath it

The FDA's stated reason: "Currently, first-in-human clinical trials may take up to two years to complete in the United States. The same types of trials are completed much faster in China and Australia, threatening America's leadership in scientific innovation."

⚠ That comparison is the agency's own, and the announcement attaches no figure or citation to it. It is quoted here as the FDA's assertion because it is the stated motivation for the pilot — not because this desk has checked it.

What does not change

The release is unusually explicit on this, and it is the sentence worth keeping:

The FDA retains full regulatory authority throughout the program, including responsibility for determining whether a clinical investigation may proceed, whether a clinical hold should be imposed, and all other regulatory oversight.

A partner institution helps assemble the application. It does not decide anything.

Where this could end up

The pilot is framed as evidence-gathering for something larger: it "may inform future policy initiatives which may result in a formal accreditation model that would recognize QRIs demonstrating strong scientific and regulatory judgment".

An accreditation model is a standing institutional arrangement, not a pilot. That is the thing to watch for after this cohort reports — and the reason to note that this one closes on October 30 with eight to ten pairs in it.

Source links